Literature DB >> 29103750

Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy.

Nicole C Schmitt1, Hyunseok Kang2, Arun Sharma3.   

Abstract

Salivary duct carcinoma (SDC) is a rare, aggressive salivary malignancy that is often diagnosed at an advanced stage. Previously, little was known about outcomes of this disease due to its rarity. In the past several years, much has been learned about salivary duct carcinoma after publication of outcomes from several large single-institution series and national database searches. Recent studies of genomic alterations have helped elucidate the biology and pathogenesis of this aggressive disease. Here we review outcomes of the disease, effects of treatment, prognostic factors, and genomic alterations in SDC. Studies of targeted therapy and promising future directions are also discussed.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ErbB2; Salivary duct carcinoma; Salivary malignancy

Mesh:

Year:  2017        PMID: 29103750      PMCID: PMC5685667          DOI: 10.1016/j.oraloncology.2017.09.008

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  87 in total

1.  [Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma].

Authors:  O Kleinsasser; H J Klein; G Hübner
Journal:  Arch Klin Exp Ohren Nasen Kehlkopfheilkd       Date:  1968

2.  Blockade of Androgen-induced Malignant Phenotypes by Flutamide Administration in Human Salivary Duct Carcinoma Cells.

Authors:  Y U Kamata; Tomoki Sumida; Ryuichi Murase; Hiroyuki Nakano; Tomohiro Yamada; Yoshihide Mori
Journal:  Anticancer Res       Date:  2016-11       Impact factor: 2.480

3.  Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases.

Authors:  Michael Jaehne; Kerstin Roeser; Thorsten Jaekel; Jan David Schepers; Natalie Albert; Thomas Löning
Journal:  Cancer       Date:  2005-06-15       Impact factor: 6.860

4.  Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance.

Authors:  Michelle D Williams; Dianna B Roberts; Merrill S Kies; Li Mao; Randal S Weber; Adel K El-Naggar
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

5.  Prognostic factors of recurrence in salivary carcinoma ex pleomorphic adenoma, with emphasis on the carcinoma histologic subtype: a clinicopathologic study of 43 cases.

Authors:  Nora Katabi; Daniel Gomez; David S Klimstra; Diane L Carlson; Nancy Lee; Ronald Ghossein
Journal:  Hum Pathol       Date:  2010-03-24       Impact factor: 3.466

6.  Expression of peroxisome proliferator-activated receptor gamma in salivary duct carcinoma: immunohistochemical analysis of 15 cases.

Authors:  Perkins Mukunyadzi; Lingbao Ai; Didier Portilla; E Leon Barnes; Chun-Yang Fan
Journal:  Mod Pathol       Date:  2003-12       Impact factor: 7.842

7.  Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes.

Authors:  Silvana Di Palma; Roderick H W Simpson; Caterina Marchiò; Alena Skálová; Marco Ungari; Ann Sandison; Stephen Whitaker; Suzanne Parry; Jorge S Reis-Filho
Journal:  Histopathology       Date:  2012-10       Impact factor: 5.087

8.  Salivary duct carcinoma--a highly aggressive salivary gland tumour with overexpression of c-erbB-2.

Authors:  H B Hellquist; M G Karlsson; C Nilsson
Journal:  J Pathol       Date:  1994-01       Impact factor: 7.996

9.  Salivary duct carcinoma.

Authors:  R T Grenko; P Gemryd; M Tytor; P G Lundqvist; B Boeryd
Journal:  Histopathology       Date:  1995-03       Impact factor: 5.087

10.  Clinical Outcomes and Prognostic Factors for Salivary Duct Carcinoma: A Multi-Institutional Analysis of 141 Patients.

Authors:  Kuninori Otsuka; Yorihisa Imanishi; Yuichiro Tada; Daisuke Kawakita; Satoshi Kano; Kiyoaki Tsukahara; Akira Shimizu; Hiroyuki Ozawa; Kenji Okami; Akihiro Sakai; Yuichiro Sato; Yushi Ueki; Yukiko Sato; Toyoyuki Hanazawa; Hideaki Chazono; Kaoru Ogawa; Toshitaka Nagao
Journal:  Ann Surg Oncol       Date:  2016-01-20       Impact factor: 5.344

View more
  12 in total

Review 1.  Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment.

Authors:  Masato Nakaguro; Yuichiro Tada; William C Faquin; Peter M Sadow; Lori J Wirth; Toshitaka Nagao
Journal:  Cancer Cytopathol       Date:  2020-05-18       Impact factor: 5.284

2.  Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression.

Authors:  Kyriakos Chatzopoulos; Andrea R Collins; Sotiris Sotiriou; Michael G Keeney; Daniel W Visscher; Michael Rivera; David J Schembri-Wismayer; Jean E Lewis; Patricia T Greipp; William R Sukov; Ashish V Chintakuntlawar; Katharine A Price; Joaquin J Garcia
Journal:  Head Neck Pathol       Date:  2020-04-29

3.  Salivary duct carcinoma: evaluation of treatment and outcome in a tertiary referral institute.

Authors:  Ann-Jean C C Beck; Peter J F M Lohuis; Abrahim Al-Mamgani; Laura A Smit; Willem M C Klop
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-05-21       Impact factor: 2.503

Review 4.  Liquid Biopsy in Head and Neck Cancer: Current Evidence and Future Perspective on Squamous Cell, Salivary Gland, Paranasal Sinus and Nasopharyngeal Cancers.

Authors:  Santiago Cabezas-Camarero; Pedro Pérez-Segura
Journal:  Cancers (Basel)       Date:  2022-06-09       Impact factor: 6.575

5.  Radiotherapy as salvage treatment of salivary duct carcinoma in major salivary glands without radical operations.

Authors:  Lu Di; Kai Qian; Chengrun Du; Chunying Shen; Ruiping Zhai; Xiayun He; Xiaoshen Wang; Tingting Xu; Chaosu Hu; Hongmei Ying
Journal:  Cancer Manag Res       Date:  2018-11-21       Impact factor: 3.989

6.  Evaluation of Prognostic Factors for the Parotid Cancer Treated With Surgery and Postoperative Radiotherapy.

Authors:  Yong-Hyub Kim; Woong-Ki Chung; Jae-Uk Jeong; Ick Joon Cho; Mee Sun Yoon; Ju-Young Song; Taek-Keun Nam; Sung-Ja Ahn; Dong Hoon Lee; Tae Mi Yoon; Joon Kyoo Lee; Sang Chul Lim
Journal:  Clin Exp Otorhinolaryngol       Date:  2019-09-05       Impact factor: 3.372

7.  Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.

Authors:  Stacey M Gargano; Wijendra Senarathne; Rebecca Feldman; Elena Florento; Phillip Stafford; Jeffrey Swensen; Semir Vranic; Zoran Gatalica
Journal:  Cancer Med       Date:  2019-10-14       Impact factor: 4.452

8.  A population-based competing risk survival analysis of patients with salivary duct carcinoma.

Authors:  Jianchuan Ran; Huihui Zou; Xiaoye Li; Feng Guo; Wenguang Xu; Wei Han
Journal:  Ann Transl Med       Date:  2020-11

9.  Contemporary Management of Benign and Malignant Parotid Tumors.

Authors:  Jovanna Thielker; Maria Grosheva; Stephan Ihrler; Andrea Wittig; Orlando Guntinas-Lichius
Journal:  Front Surg       Date:  2018-05-11

10.  Trophoblast Cell Surface Antigen 2 (Trop-2) Protein is Highly Expressed in Salivary Gland Carcinomas and Represents a Potential Therapeutic Target.

Authors:  Philipp Wolber; Lisa Nachtsheim; Franziska Hoffmann; Jens Peter Klußmann; Moritz Meyer; Ferdinand von Eggeling; Orlando Guntinas-Lichius; Alexander Quaas; Christoph Arolt
Journal:  Head Neck Pathol       Date:  2021-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.